Moderna's Melanoma Data Impress, but Approval Clock and Valuation Gap Keep Investors Wary

Positive clinical data do not automatically translate into a rising share price. Moderna demonstrated that disconnect this week: the stock fell 4.4% today, extending a sell-off that began when melanoma trial results leaked ahead of schedule.

The detailed Phase 3 INTerpath-001 data, released yesterday by Merck and Moderna, showed the combination of intismeran autogene and KEYTRUDA cut the risk of recurrence or death by 42% versus KEYTRUDA alone, with a median follow-up of 24.6 months. The study enrolled 1,137 patients whose melanoma had been completely removed (stages IIB–IV). A secondary finding showed a 38% reduction in the risk of distant metastasis or death compared with KEYTRUDA monotherapy.

The clinical signal is clear. What it does not do is settle the investment case. A risk reduction in a trial is neither a revenue forecast nor a return projection for shareholders — a distinction that matters more than ever after the market's negative reception.

A Leak, a Sell-Off, and Two Different Yardsticks

The detailed results had leaked before their planned presentation, according to Reuters. The stock lost 17% yesterday as the early data fell short of elevated market expectations, then shed another 4.4% today. Bernstein described the results as strong and a validation of the platform, framing the decline as profit-taking after the news broke. Citi's Geoff Meacham took a different view: he called the data clinically meaningful but weaker than the market had anticipated, noting that valuations had also priced in success in other solid tumors.

That divergence captures the tension running through the Moderna story. Investors are not judging the quality of a news release in isolation — they are deciding what economic value to assign it. Reading the falling share price as a refutation of the science confuses two separate measures, just as treating the dip as a bargain entry point would be a shortcut.

Should investors sell immediately? Or is it worth buying Moderna?

The Regulatory Path Is Measured in Years, Not Weeks

The Melanoma Institute Australia emphasized today that the results will feed into regulatory review, a process that could take several years depending on the jurisdiction. Until then, the treatment will not be available. A completed trial is not secured market access.

Moderna and Merck are in talks with regulators and, according to Reuters, preparing a US marketing application. The near-term scenario rests on a narrowly defined indication — resected high-risk melanoma — rather than an immediate expansion across multiple cancer types. A projected market launch in 2027 remains a forecast, not a confirmed date.

On the evidence front, no new safety signals were reported, and the results have been accepted for publication in the New England Journal of Medicine. Both facts reinforce the scientific foundation without pre-empting any regulatory decision.

What the Numbers Show — and What They Don't

The benchmark that matters most is the incremental benefit over KEYTRUDA alone. At two years, 82.2% of patients on the combination were alive and recurrence-free, against 70.0% on KEYTRUDA monotherapy. A prespecified analysis offered a further positive signal: among patients who remained recurrence-free beyond the first six months, the risk reduction reached 58%. That subgroup finding, however, covers a limited population and does not replace the result for the full study cohort.

Overall survival benefit cannot yet be determined. Nor do earlier trial readings offer a simple yardstick, since differences in patient populations and follow-up periods limit comparability. A smaller risk reduction than in prior studies is not automatically a clinical step backward — though it can dampen expectations for the platform.

Citi's Meacham raised a further question: the added benefit relative to earlier-line immunotherapy, weighed against the burden of individual tumor sampling and manufacturing. The risk therefore extends beyond efficacy. The cost and complexity of a personalized therapy must be justified by its incremental value. Citi reiterated its sell rating and its $80 price target.

The Calendar Ahead

The next concrete checkpoint is tomorrow's presentation at the ESMO congress in Madrid, which should provide the detailed scientific context for the data. On November 6, Moderna reports third-quarter 2026 results alongside a corporate update.

Until then, investors face a two-track assessment. The clinical benefit is documented. The timing, scope, and commercial worth of a potential approval still have to take shape. In the favorable scenario, tangible regulatory progress would narrow the gap between trial success and economic outlook. In the less favorable one, a narrower label or a longer review — even without the therapy failing outright — could disappoint expectations that stretch well beyond melanoma.

Ad

Moderna Stock: New Analysis - 23 October

Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Moderna analysis...